Cover Image

EMERGING PARADIGMS IN DELIVERY SYSTEMS FOR ANTITUBERCULAR THERAPY.

Emerging Paradigms in Delivery Systems for Antitubercular Therapy provides an up-to-date and thorough overview of the state-of-the-art of concepts, design, and recent advances in nanomedicines and nanobiotechnology-based strategies for the treatment of tuberculosis.

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Format: eBook
Language:English
Published: [S.l.] : ELSEVIER ACADEMIC PRESS, 2025.
Subjects:
Tuberculosis > Vaccination.
Tuberculosis > Treatment.
Drug delivery systems.
Nanomedicine.
Drug Delivery Systems
Nanomedicine
Tuberculose > Traitement.
Systèmes d'administration de médicaments.
Nanomédecine.
Tuberculose > Vaccination.
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Front Cover
  • EMERGING PARADIGMS IN DELIVERY SYSTEMS FOR ANTITUBERCULAR THERAPY
  • Copyright
  • Contents
  • List of contributors
  • 1 Introduction: An overview of novel approaches for the treatment of tuberculosis
  • 1.1 Introduction
  • 1.2 Morbific of tuberculosis
  • 1.2.1 Inhalation of the bacteria
  • 1.2.2 Inflammatory cell recruitment
  • 1.2.2.1 Control of bacterial proliferation
  • 1.2.3 Postprimary tuberculosis
  • 1.3 Current therapies available for tuberculosis
  • 1.4 Limitation of current therapies
  • 1.5 Novel drug conveyance arrangements for tuberculosis
  • 1.5.1 Novel therapeutics approved for tuberculosis treatment
  • 1.5.1.1 Bedaquiline
  • 1.5.1.2 Delamanid
  • 1.5.1.3 PA-824
  • 1.5.1.4 Sutezolid
  • 1.5.1.5 AZD5847
  • 1.5.1.6 SQ109
  • 1.6 Novel delivery systems
  • 1.6.1 Nanoparticles and Microparticles
  • 1.6.2 Liposomes
  • 1.6.3 Niosomes
  • 1.6.4 Biodegradable microspheres
  • 1.6.5 Nanocapsules
  • 1.6.6 Dendrimers
  • 1.6.7 Nanoemulsion
  • 1.7 Clinical trials involved in novel formulations for tuberculosis
  • 1.8 Toxicity studies of novel formulation
  • 1.9 Patents on novel formulation for tuberculosis
  • 1.10 Conclusion
  • References
  • 2 Theragnostic approaches for the management of tuberculosis
  • 2.1 Introduction
  • 2.2 Tuberculosis: classification and therapeutic options
  • 2.2.1 Classification of tuberculosis
  • 2.2.1.1 Active tuberculosis
  • 2.2.1.2 Latent tuberculosis
  • 2.2.2 Treatment of tuberculosis
  • 2.2.3 Vaccination of tuberculosis
  • 2.3 Conventional dosage forms for tuberculosis
  • 2.3.1 Challenges and barriers of therapy
  • 2.4 Novel drug delivery systems for tuberculosis management
  • 2.4.1 Inhalable micro/nanoparticles
  • 2.4.1.1 Poly lactic-co-glycolic acid
  • 2.4.1.2 Chitosan
  • 2.4.2 Vesicular systems
  • 2.4.2.1 Liposomes
  • 2.4.2.2 Niosomes
  • 2.4.2.3 Exosomes
  • 2.4.3 Supramolecular assembly systems.
  • 2.4.3.1 Multifunctional micelles
  • 2.4.3.2 Dendrimers
  • 2.4.4 Ligand-driven nanomedicines
  • 2.5 Theragnostic approaches for tuberculosis management
  • 2.5.1 Gold nanoparticles
  • 2.5.2 Carbon nanotubes
  • 2.5.3 Copper nanoparticles
  • 2.5.4 Fullerenes
  • 2.6 Conclusion and future perspectives
  • References
  • 3 Role of metallic nanoparticles in the treatment of tuberculosis
  • 3.1 Introduction
  • 3.2 Pathophysiology of tuberculosis
  • 3.3 Challenges for drug delivery in drug-resistant tuberculosis
  • 3.4 Metal nanoparticles-driven strategies for the treatment of tuberculosis
  • 3.4.1 Silver nanoparticles-based strategies for the management of tuberculosis
  • 3.4.2 Zinc oxide nanoparticles-based strategies for the treatment of tuberculosis
  • 3.4.3 Gold nanoparticles-based strategies for tuberculosis
  • 3.4.4 Iron-oxide nanoparticles-based strategies for tuberculosis
  • 3.4.5 Magnesium oxide nanoparticles-based strategies for tuberculosis
  • 3.4.6 Gallium nanoparticles-based strategies for tuberculosis
  • 3.4.7 Titanium dioxide nanoparticles-based strategies for tuberculosis
  • 3.4.8 Selenium nanoparticles-based strategies for tuberculosis
  • 3.5 Regulatory overview and toxicity of metal nanoparticles
  • 3.6 Conclusion and future prospects
  • Acknowledgment
  • References
  • 4 Role of biodegradable polymeric nanoparticles for the treatment of tuberculosis
  • 4.1 Introduction of nanomaterials
  • 4.1.1 Preparation of nanoparticles
  • 4.1.2 Preparation of polymeric nanoparticles
  • 4.1.2.1 Dispersion of performed polymers
  • 4.1.2.1.1 Solvent evaporation method
  • 4.1.2.1.2 Salting out method
  • 4.1.2.1.3 Solvent displacement/ nanoprecipitation
  • 4.1.2.2 Polymerization techniques of various monomers
  • 4.1.2.2.1 Emulsion polymerization
  • Interfacial polymerization
  • 4.1.2.3 Coacervation or Ionic gelation method of hydrophilic polymers.
  • 4.1.2.4 Supercritical fluid technology
  • 4.1.2.4.1 Techniques using the supercritical fluid as a solvent
  • Rapid expansion of supercritical solutions
  • 4.1.2.4.2 Techniques using the supercritical fluid as an antisolvent
  • Supercritical fluid antisolvent
  • 4.2 Advance methods for preparation of nanoparticles
  • 4.2.1 Spray drying technique
  • 4.2.2 Sol-gel technique
  • 4.2.3 High pressure homogenization
  • 4.2.4 Desolvation of macromolecules
  • 4.2.5 Dialysis
  • 4.3 Biodegradable polymeric nanocarriers for the delivery of antitubercular drugs
  • 4.4 Conclusion
  • References
  • 5 Role of vesicular nanocarriers for the treatment of tuberculosis
  • Abbreviations
  • 5.1 Introduction
  • 5.1.1 Current scenario and epidemiology of tuberculosis-pulmonary, extrapulmonary tuberculosis
  • 5.2 Barriers and strategies to overcome in tubercular disease
  • 5.2.1 Pulmonary barriers
  • 5.2.1.1 Pulmonary surfactant
  • 5.2.1.2 Respiratory mucus
  • 5.2.1.3 Airway epithelium
  • 5.2.2 Intravascular barriers
  • 5.2.3 Intracellular barriers
  • 5.2.3.1 Endocytosis
  • 5.2.3.2 Granuloma
  • 5.2.3.3 Alveolar macrophages
  • 5.3 Conventional therapies
  • 5.3.1 Surgical treatment
  • 5.3.2 Chemotherapy
  • 5.3.3 Radiotherapy
  • 5.4 Limitations of conventional therapy
  • 5.4.1 Antimicrobial resistance
  • 5.5 Need for nanocarriers-based drug delivery system in tuberculosis management
  • 5.6 Various vesicular nanocarriers and targeting approaches in tuberculosis management
  • 5.6.1 Liposomes
  • 5.6.2 Polymersomes
  • 5.6.3 Niosomes
  • 5.6.4 Cubosomes
  • 5.6.5 Transferosomes
  • 5.6.6 Archaeosomes
  • 5.6.7 Phytosomes
  • 5.6.8 Liposhpere
  • 5.6.9 Extracellular vesicles
  • 5.6.10 Respirable/inhalable vesicular carriers
  • 5.7 Advanced application of vesicular nanocarriers
  • 5.7.1 Theranostics
  • 5.7.2 Immunotherapy
  • 5.8 Potential toxicity of vesicular nanocarrier and immune response.
  • 5.9 Current clinical status and regulatory translation
  • 5.10 Future prospectives and challenges in commercialization
  • References
  • 6 Role of carbon nanotubes for the treatment of tuberculosis
  • 6.1 Introduction
  • 6.2 Macrophage: the cellular tropics of Mycobacterium tuberculosis
  • 6.3 Challenges with current tuberculosis chemotherapy
  • 6.4 Need for engineered nanoconstructs
  • 6.5 Role of carbon nanomaterials in the treatment of tuberculosis
  • 6.5.1 Fullerene
  • 6.5.2 Carbon nanotubes
  • 6.5.3 Graphene oxides (Go)
  • 6.6 In vivo toxicity of carbon nanomaterials
  • 6.7 Role of carbon nanotubes for the treatment of tuberculosis
  • 6.8 Conclusions
  • References
  • 7 Role of the gut lung axis and microbiota based approaches in the treatment of tuberculosis
  • 7.1 Introduction
  • 7.2 Tuberculosis
  • 7.3 Microbiota and tuberculosis
  • 7.4 The gut-lung axis in tuberculosis
  • 7.5 Microbiota-based therapeutic approaches used for the treatment of tuberculosis
  • 7.6 Conclusion
  • References
  • 8 Mucoadhesive polymeric nanocarriers for the treatment of tuberculosis
  • 8.1 Introduction
  • 8.2 Current approaches to tuberculosis treatment and their limitations
  • 8.3 Mucoadhesion in drug delivery: an overview
  • 8.3.1 Key principles of mucoadhesion
  • 8.4 Applications of mucoadhesive drug delivery systems
  • 8.4.1 Benefits of mucoadhesive drug delivery systems
  • 8.4.2 New advancements utilizing polymeric nanocarriers for tuberculosis management
  • 8.4.2.1 Nanocarrier types for tuberculosis treatment
  • 8.4.2.2 Benefits of polymeric nanocarriers in tuberculosis treatment
  • 8.4.2.3 Challenges and continuing investigations
  • 8.5 Mucoadhesion
  • 8.5.1 Physical interactions
  • 8.5.2 Biological interactions
  • 8.5.3 Applications in tuberculosis treatment
  • 8.5.4 Challenges and future directions
  • 8.5.5 Potential strategies to overcome challenges.
  • 8.5.6 Ongoing research and future prospects
  • 8.6 Applications of mucoadhesives in the treatment of tuberculosis
  • 8.6.1 Targeted drug delivery
  • 8.6.2 Enhanced bioavailability
  • 8.6.3 Sustained release
  • 8.6.4 Reduced systemic toxicity
  • 8.6.5 Reduced drug resistance
  • 8.6.6 Other applications
  • 8.7 Conclusion
  • References
  • 9 Recent gene therapy approaches for the treatment of tuberculosis
  • 9.1 Introduction
  • 9.1.1 Understanding tuberculosis: causes and challenges
  • 9.1.2 Exploring gene therapy as a promising treatment avenue
  • 9.2 Gene delivery mechanisms: viral and nonviral vectors
  • 9.3 Characteristics of viral vectors used in gene therapy treatment of tuberculosis
  • 9.3.1 Target cells and tissues in tuberculosis gene therapy
  • 9.4 Recent advances in tuberculosis gene therapy
  • 9.4.1 CRISPR-Cas9 technology
  • 9.4.2 RNA interference
  • 9.4.3 CRISPR-Cas 9 technology: editing tuberculosis related genes
  • 9.4.4 RNA interference: silencing pathogenic factors
  • 9.5 Challenges and considerations
  • 9.5.1 Safety concerns and off-target effects
  • 9.5.2 Ethical and regulatory considerations
  • 9.5.3 Personalized approaches: tailoring gene therapy for patients
  • 9.6 Conclusion
  • 9.6.1 A gene therapy-enhanced future for tuberculosis treatment
  • References
  • 10 Novel targets and drugs for the treatment of tuberculosis
  • 10.1 Introduction
  • 10.2 Cell wall biosynthesis
  • 10.3 Peptidoglycans synthesis
  • 10.4 Mycolic acid
  • 10.5 Arabinogalactan biosynthesis
  • 10.6 Amino acid biosynthesis
  • 10.6.1 Arginine biosynthesis
  • 10.6.2 Shikimic acid pathway
  • 10.7 Branched-chain amino acid biosynthesis
  • 10.8 Cofactor biosynthesis
  • 10.8.1 Folic acid biosynthesis
  • 10.9 Pantothenic acid biosynthesis
  • 10.10 Coenzyme A biosynthesis
  • 10.11 Riboflavin biosynthesis
  • 10.12 Mycothiol biosynthesis
  • 10.13 Terpenoid biosynthesis.